MediGene touts new breast cancer data; Cayman Islands court to review WuXi buyout;

@FierceBiotech: Self-assembling DNA used in nanoscale delivery system. Article | Follow @FierceBiotech

 @JohnCFierce: Only a few days ago Pfizer researchers were describing tanezumab's PhIII data as "extraordinary." Today, not so much. | @JohnCFierce

> Germany's MediGene says that additional Phase II breast cancer data on EndoTAG-1 confirm a positive efficacy trend. MediGene release

> While GSK's leukemia drug Arzerra has been conditionally approved in the U.S. and the U.K., NICE says the NHS shouldn't have to pay for it. Story

> A Cayman Islands court will meet on Tuesday to review the $1.6 billion buyout of WuXi PharmaTech by Charles River Laboratories. Report

> Canada's Thallion Pharmaceuticals has paid $2.4 million to get out of its lease in Montreal as it scouts for a new headquarters. Story

> Bioheart says it has named Mike Tomas was named president and chief executive officer, replacing Karl Groth, who stays on as chairman. Tomas is president of The Astri Group, a private equity firm. The developer's last management shakeup took place less than a year ago. Report

And Finally... Xconomy has updated its guide to venture incubators. Report